Dutasteride, a 5 alpha reductase inhibitor, could be associated with the exacerbation of inflammation in patients with benign prostatic hyperplasia.

Background: α-1 blockers and dutasteride are widely used as agents to treat benign prostatic hyperplasia (BPH); the impact of these drugs on prostatic inflammation is still unclear. Herein, we investigated the impact of α-1 blockers and dutasteride treatment of BPH in terms of the degree of prostatic inflammation.

Materials And Methods: Tissue specimens were obtained from 143 BPH patients who were administered α-1 blockers up until their operation.

[A CASE OF MUCIN-PRODUCING UROTHELIAL-TYPE ADENOCARCINOMA OF THE PROSTATE (MPUAP) WITH LONG-TERM SURVIVAL AFTER TOTAL CYSTECTOMY].

Mucin-producing urothelial-type adenocarcinoma of the prostate (MPUAP) is a very rare disease. MPUAP has been reported to progress faster than the rate at which normal prostate cancer progresses. We report a case of MPUAP with long-term survival.